# Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

> **NCT00988169** · PHASE2 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** oral erlotinib and pulsed doses of oral AT-101

## Key facts

- **NCT ID:** NCT00988169
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2015-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00988169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00988169, "Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00988169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*